KalVista Corp (KALV) - Long-Term Debt to Capital Coefficient

KalVista Pharmaceuticals (KALV) adheres to green chemistry principles, minimizing harmful emissions and conserving water during drug development. The business leverages AI and automation to accelerate the discovery of molecules for treating rare pathologies. The asset's market value dynamics, standing at 0.00, confirm the resilience of the brand's position, which is protected by exclusive FDA patents and massive R&D expenditures that create high barriers to entry for new players.

This indicator measures the degree of financial leverage by comparing long-term borrowings against total equity to assess the stability of the balance sheet structure. By analyzing the ratio of liabilities exceeding one year to equity, an investor determines the solvency risk of KalVista Pharmaceuticals (KALV), whose outsourcing model for clinical trials and manufacturing increases dependence on external contractors when servicing the debt load.